Granulomatosis with polyangiitis induced by the anti-programmed cell death-1 inhibitor tislelizumab: A case report

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 15

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. May 26, 2025; 13(15): 103239
Published online May 26, 2025. doi: 10.12998/wjcc.v13.i15.103239

Full Size Figure Download Figure

Figure 3 Renal function during the patient’s treatment. BUN: Blood urea nitrogen; SCR: Serum creatinine; UA: Uric acid.

Citation: Zhao JH, Wang JJ, Li YW. Granulomatosis with polyangiitis induced by the anti-programmed cell death-1 inhibitor tislelizumab: A case report. World J Clin Cases 2025; 13(15): 103239
URL: https://www.wjgnet.com/2307-8960/full/v13/i15/103239.htm
DOI: https://dx.doi.org/10.12998/wjcc.v13.i15.103239

Zhao JH, Wang JJ, Li YW. Granulomatosis with polyangiitis induced by the anti-programmed cell death-1 inhibitor tislelizumab: A case report. World J Clin Cases 2025; 13(15): 103239 [PMID: 40420929 DOI: 10.12998/wjcc.v13.i15.103239]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.